At the summer meeting of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, ZEISS is substantiating its unique portfolio of intraocular lenses with new study results. An improved data management connection, an additional slit lamp model and a surgical microscope for primary health care ensure convincing results in basic diagnostics. Operations have meanwhile been performed on more than 250,000 eyes using the innovative SMILE procedure for refractive corrections.
The special focus this year is on the Premium intraocular lenses (IOL) of the AT LISA® tri product family which are so highly esteemed by physicians due to impressive clinical data. According to a study by Professor Jorge Alió of the Miguel Hernández University in Alicante, Spain, patients who received the trifocal IOL AT LISA® tri in both eyes were satisfied with their vision in different conditions and distances, and rated them as excellent or very good. In particular the trifocal lenses from ZEISS, according to the studies of Professor Alió, produced excellent results with respect to contrast sensitivity.1 “Without exception all patients would recommend this type of IOL2,” says Professor Alió. In addition to trifocal IOLs, monofocal IOLs and IOLs in both hydrophilic and hydrophobic materials are still available to ZEISS customers – making it the broadest portfolio of IOLs which since 2014 has been rounded off by the CT LUCIA® monofocal hydrophobic IOL.
For basic diagnostics, at the trade fair ZEISS will be unveiling the SL 220 slit lamp with the familiar tower design. It thus now offers the two common operating concepts for slit lamps. The LED illumination and the optomechanical properties of the SL 220 assist physicians in the diagnosis of eye diseases - in renowned ZEISS quality.
With the VISUCONNECT 500® software ZEISS introduces easy data management to basic diagnostics. Now patient data recorded with the ZEISS pre-surgery diagnostic instruments for objective refraction and measurement of intraocular pressure, can be automatically transmitted to electronic patient files or practice management systems, e.g. ZEISS FORUM®. FORUM® is an ophthalmic data management system which helps increase the efficiency of eye care practices and clinics. It supports eye care professionals in meeting their everyday challenges.
The new OPMI LUMERA® 300 from ZEISS brings the advantages of the OPMI LUMERA series to the routine segment. The device offers an excellent price/performance ratio and requires a lower light intensity. This makes treatment less stressful for patients. In ophthalmic surgery, physicians benefit from the renowned quality of optics and illumination of the OPMI LUMERA product range. “With this surgical microscope ZEISS is expanding its product range for primary health care, particularly for customers in the fast-growing Asian markets,” says Dr Ludwin Monz, Chief Executive of Carl Zeiss Meditec AG.
The innovative SMILE procedure has developed very successfully for ZEISS in the premium segment. Since its approval in 2011 over 250,000 eyes have been treated successfully by this method, to date the only minimally invasive procedure for refractive laser correction available worldwide. There are meanwhile 350 clinics and practices throughout the world with more than 700 refractive surgeons who are proficient in the SMILE method and offer this procedure to their patients. Some surgeons have operated on more than 10,000 eyes. “With SMILE we have introduced a procedure to refractive surgery that provides great benefits with currently the smallest possible intervention. The cornea of the eye remains intact as far as possible , accompanied by a high degree of predictability of the correction. The results are convincing more and more physicians and patients worldwide,” says Dr. Ludwin Monz.
The procedure has established itself in key markets such as Europe, China and India. Studies in the USA are being extended. A first comprehensive study on spherical myopia has been almost completed and physicians at five clinics have enrolled the first 100 patients as part of a further study on myopia with astigmatism.
ZEISS is also presenting further ophthalmic innovations for retina and glaucoma diagnostics.
OCT is the standard procedure for retina and glaucoma diagnostics. It is also used for preoperative assessment prior to cataract surgery. ZEISS is extending its portfolio in optical coherence tomography (OCT) to include a compact solution: PRIMUS 200, which has already been introduced to the Indian market and now approved for sale in Europe, is an easy-to-operate and versatile device with the main applications for diagnosis of the anterior and posterior segment of the eye. It offers new opportunities in clinical care, particularly to physicians in smaller eye care practices. The smaller footprint, simple design and short learning curve will make it easy to integrate the PRIMUS 200 into such practices. This product is not available in the USA.
ZEISS AngioPlex OCT Angiography assists physicians in displaying the blood vessels of the patient's retina without having to inject fluorescent liquids. The retina and choroid can be examined with the aid of optical coherence tomography non-invasively in three-dimensional representations. This facilitates clinical decisions for physicians. “We expect the procedure to have the potential to replace the current gold standard in fluorescence angiography. It constitutes a real step forward for physicians and patients in non-invasive diagnosis of the eye,” says Dr Ludwin Monz. While physicians can now closely observe vascular changes with the aid of OCT technology, the risks for patients associated with an intervention by fluorescent dyes are eliminated. In addition, practice workflow is accelerated. ZEISS AngioPlex OCT Angiography is the first such technology that has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The company will be presenting the ZEISS Retina Suite for retinal diagnostics. The solution consists of a CIRRUS HD-OCT with the AngioPlex OCT Angiography application and Retina Workplace, an ophthalmic software from ZEISS that makes it easier for physicians to manage macular diseases. The ZEISS Retina Suite solution integrates quality imaging, at-a-glance diagnostic history and an interactive review to support accelerated clinic flow and insightful assessment. “It effectively supports retina specialists in recognizing and treating retinal disease,” says Dr. Ludwin Monz.
With the HFA3 perimeter, introduced to the US market in March, ZEISS is setting new standards in visual field diagnosis. The HFA3 eliminates the time-consuming and error-prone manual replacement of corrective lenses; the examination workflow is optimized. The test results on the new platform are compatible with those of the earlier generation of HFA devices and harmonize well with progression analysis without loss of quality in progress monitoring.
In addition to the HFA3, CIRRUS HD-OCT with the new Anterior Segment Premier module is an integral part of the ZEISS Glaucoma Suite to be showcased at the ESCRS. CIRRUS HD-OCT with the new Anterior Segment Premier Module, delivers for the first time complete imaging of the anterior chamber of the eye to assist physicians in the diagnosis of glaucoma with OCT.
1 Alió, J. L.: “Outcomes of a new diffractive trifocal intraocular lens”; Mojzis P, Alió JL et al., published in: Cataract & Refractive Surgery Today 2014; 40:60-69.
2 This can be found in the following study: Alió, J.L. & J. Pikkel (2014): Multifocal Intraocular Lenses. The Art and the Practice. In: Singh, A. D. (Publisher): Essentials in Ophthalmology. Springer. p. 207.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. With almost 3,000 employees, the Group generated revenue of € 909 million in financial year 2013/2014 (to 30 September).
The head office of Carl Zeiss Meditec is in Jena, Germany. The Company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
Carl Zeiss offers innovative solutions for the future-oriented markets Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.
For more information visit our website at: